Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 12;51(4):1702114.
doi: 10.1183/13993003.02114-2017. Print 2018 Apr.

Multimorbidity medications and poor asthma prognosis

Sébastien Chanoine  1   2   3 , Margaux Sanchez  4   5 , Isabelle Pin  1   6 , Sofia Temam  4   5   7 , Nicole Le Moual  4   5 , Agnès Fournier  8   9 , Christophe Pison  3   10   11 , Jean Bousquet  4   5   12   13 , Pierrick Bedouch  2   3   14 , Marie-Christine Boutron-Ruault  8   9 , Raphaëlle Varraso  4   5 , Valérie Siroux  1
Affiliations
Free article

Multimorbidity medications and poor asthma prognosis

Sébastien Chanoine et al. Eur Respir J. .
Free article

Abstract

Multimedication related to multimorbidity is common in the elderly with asthma. We aimed at comprehensively characterising medications used by elderly women and assessing how multimedication impacts on asthma prognosis.We performed network-based analyses on drug administrative databases to visualise the prevalence of drug classes and their interconnections among 17 458 elderly women from the Asthma-E3N study, including 4328 women with asthma. Asthma groups sharing similar medication profiles were identified by a clustering method relying on all medications and were studied in association with adverse asthma events (uncontrolled asthma, attacks/exacerbations and poor asthma-related quality of life).The network-based analysis showed more multimedication in women with asthma than in those without asthma. The clustering method identified three multimedication profiles in asthma: "Few multimorbidity-related medications" (43.5%), "Predominantly allergic multimorbidity-related medications" (32.8%) and "Predominantly metabolic multimorbidity-related medications" (23.7%). Compared with women belonging to the "Few multimorbidity-related medications" profile, women belonging to the two other profiles had an increased risk of uncontrolled asthma and asthma attacks/exacerbations, and had lower asthma-related quality of life.The integrative data-driven approach on drug administrative databases identified specific multimorbidity-related medication profiles that were associated with poor asthma prognosis. These findings support the importance of multimorbidity in the unmet needs in asthma management.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest: S. Chanoine reports personal fees (board membership) from AstraZeneca, and nonfinancial support (travel/accommodation/meeting expenses) from Boehringer Ingelheim, Actelion Pharmaceuticals and MSD, outside the submitted work. I. Pin reports travel grants and presentation fees from Novartis and AstraZeneca, and fees for training courses from Vertex, outside the submitted work. C. Pison has received grants and lectures fees from GlaxoSmithKline, AstraZeneca, Novartis and BIF, as well as speaker fees and fees for meeting participation from GlaxoSmithKline, AstraZeneca, Novartis, BIF and Teva. J. Bousquet reports personal fees (scientific and advisory boards) from Almirall, Meda, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, as well as personal fees (lecture fees) from Almirall, AstraZeneca, Chiesi, GlaxoSmithKline, Meda, Menarini, Merck, MSD, Novartis, Sanofi-Aventis, Takeda, Teva and Uriach, outside the submitted work. P. Bedouch reports fees for meeting expenses from Actelion Pharmaceuticals, outside the submitted work. R. Varraso reports grants from the Institut pour la Recherche en Santé Publique (IReSP), during the conduct of the study. V. Siroux reports personal fees (speakers honorarium) from Teva, AstraZeneca and Novartis, outside the submitted work.

References

    1. Mediators Inflamm. 2016;2016:3690628 - PubMed
    1. Eur J Clin Pharmacol. 2012 Feb;68(2):123-9 - PubMed
    1. Eur Respir J. 2014 Sep;44(3):775-88 - PubMed
    1. Chest. 2016 Jun;149(6):1525-34 - PubMed
    1. BMJ. 2015 Jan 20;350:h176 - PubMed

Publication types

LinkOut - more resources